Abbott Laboratories (ABT) Stock Faces Margin Squeeze As Net Profit Slide Tests Growth Narrative

Abbott Laboratories (ABT) just posted Q2 2026 revenue of about US$12.6b with basic EPS of US$0.53, alongside trailing twelve month revenue of roughly US$46.6b and EPS of US$3.11. Over recent quarters the company has seen revenue move from about US$11.1b in Q2 2025 to US$12.6b in Q2 2026, while quarterly EPS shifted from US$1.02 to US$0.53. This sets up a results season where investors are likely to focus closely on how margins are holding up in the current mix of growth drivers.

See our full analysis for Abbott Laboratories.

With the headline numbers on the table, the next step is to weigh them against the main narratives around Abbott Laboratories to see which stories the latest margins and earnings trends actually support and which ones get pushed back.

See what the community is saying about Abbott Laboratories

Margins Under Pressure As Net Profit Slides To 11.6%

• Over the last 12 months Abbott Laboratories reported net profit of about US$5.4b on US$46.6b of revenue, which works out to an 11.6% net margin compared with 32.4% the prior year.
• Analysts' consensus view expects profit margins to move higher over time. However, the drop from 32.4% to 11.6% means investors have to balance the long term story of expanding diagnostics and device franchises against the recent compression in profitability.
  • The consensus narrative points to strong, recurring demand from aging populations and chronic disease treatments, while the latest trailing margin shows those tailwinds are not yet reflected in reported profitability.
  • Forecast earnings growth of about 16.7% per year sits against this lower margin base, so a key question is how much of that growth comes from improving margins versus simply growing the top line.

Revenue Growth Of 7.9% Meets Higher EPS Forecasts

• Trailing revenue growth sits at 7.9% per year and five year EPS growth has averaged 7.3% per year, while analysts in the data expect earnings to grow around 16.7% per year from here.
• Consensus narrative suggests Abbott Laboratories can lean on emerging market demand and an aging population to support that higher earnings growth rate, even though recent revenue growth is below the cited 12.6% expected for the wider US market.
  • Supporters highlight growing diagnostics and medical device usage in regions like Latin America and Asia, which is consistent with the 7.9% revenue growth but not yet at the double digit pace analysts are assuming.
  • Critics can point out that with revenue growth below the broader market assumption and margins at 11.6%, the step up to mid teens EPS growth requires meaningful improvement compared with the 7.3% five year EPS trend.

On top of these growth and margin trends, it helps to see how other investors stitch the numbers together into a long term story for Abbott Laboratories through the Curious how numbers become stories that shape markets? Explore Community Narratives.

Mixed Valuation Signals At 32.5x P/E And Below DCF Fair Value

• The stock trades on a 32.5x P/E, higher than the 27.2x US Medical Equipment industry average but below the 35.9x peer average, and the provided DCF fair value of about US$144.46 sits above the current share price of roughly US$100.68.
• Consensus narrative frames this as a balance between quality and risk, with the premium P/E and lower net margin of 11.6% offset by mid teens forecast earnings growth and a roughly 2.5% dividend yield.
  • Supporters argue that a 32.5x P/E can be justified if earnings do grow around 16.7% per year and if the business mix in diagnostics and devices eventually lifts margins from the current 11.6% level.
  • Skeptics focus on the high level of debt and the margin step down from 32.4% to 11.6%, noting that paying more than the industry P/E while profitability is lower makes the DCF fair value of US$144.46 highly sensitive to how those risks play out.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Abbott Laboratories on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mixed signals around Abbott Laboratories' margins, growth and valuation, it makes sense to move quickly and test the story against your own expectations using the 3 key rewards and 2 important warning signs.

See What Else Is Out There Beyond Abbott Laboratories

Abbott Laboratories currently sits with an 11.6% net margin, a 32.5x P/E and profit trends that ask investors to accept higher valuation alongside compressed profitability.

If that trade off feels uncomfortable, use the 84 resilient stocks with low risk scores to quickly spot companies where earnings quality and risk scores may line up more closely with your expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com